Pergamum AB and Cadila Pharmaceuticals Ltd. have entered a strategic collaboration to develop a novel treatment of infections with a unique targeting mechanism different from traditional antibiotics.
The two companies will collaborate on the preclinical and clinical development of a novel therapeutic peptide developed by Pergamum AB, at Cadila’s facilities in Ahmedabad, India. Cadila will be responsible for all costs related to development through Phase II and the two companies will share global rights.
"Pergamum has developed a new class of short synthetic peptides with both anti-infective and anti-inflammatory properties derived from the body's own defense system. There is a rapidly increasing global prevalence of antibiotics resistance that limits the therapeutic value of conventional products, and we think that we can meet this need with this novel therapeutic peptide," said Jonas Ekblom, chief executive officer of Pergamum.
"This partnership combines Cadila's advanced product development capabilities with the innovative capacity of Pergamum. Cadila Pharmaceuticals bring their expertise in drug development and demonstrates that commitment towards developing affordable innovative compounds to the market in this collaboration,” said Rajiv Modi, chairman and managing director of Cadila Pharmaceuticals.
Pergamum, Cadila in Antibiotic Development Pact
Published February 8, 2013
blog comments powered by Disqus